Announcements Trials
Browse Landscape

Phase

Phase 1 8Phase 2 7Phase 1/2 3Phase NA 1

Status

Completed 3

Sponsor Class

NIH 6OTHER 3INDUSTRY 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 2Gastrointestinal 1

Conditions

Ovarian Neoplasms 2Carcinoma, Ovarian Epithelial 2Recurrence 1Pancreatic Neoplasms 1

Interventions

Cyclophosphamide 250Radiotherapy 172pembrolizumab 154Carboplatin 146Gemcitabine 139Nivolumab 135Paclitaxel 129Dexamethasone 118Cisplatin 118fludarabine 115Rituximab 104Lenalidomide 103Bevacizumab 99Docetaxel 97Capecitabine 97fludarabine phosphate 92Temozolomide 89Cytarabine 89Oxaliplatin 87Etoposide 82Filgrastim 77Irinotecan 73Doxorubicin 73venetoclax 70Peripheral Blood Stem Cell Transplantation 68Fluorouracil 68Radiosurgery 66Melphalan 66Everolimus 66Bortezomib 66

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER × veliparib × Clear all
NCT01489865 2025-11-06

ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer

Georgetown University

Phase 1/2 Completed
64 enrolled 20 charts
Gastrointestinal

Pancreatic Neoplasms

NCT01472783 2016-11-16

Veli-BRCA

Vejle Hospital

Phase 1/2 Completed
49 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Recurrence

NCT01690598 2015-06-10

Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status

Vejle Hospital

Phase 1/2 Completed
22 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡